AGMB-101 / AgomAb Therapeutics - LARVOL DELTA

Agomab Completes $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline [Google translation] (Sohu.com) - "Agomab Therapeutics NV...announced the completion of a USD 89 million (EUR 82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors....The proceeds from the Series D financing will be used to further advance the clinical development of Agomab's lead candidate, AGMB-129, a gut-restricted, oral, small molecule inhibitor of ALK5 (TGFβ1R) for patients with fibrotic Crohn's disease (FSCD). Interim data from the Phase 2a STENOVA trial are expected in the first quarter of 2025. In addition, the proceeds will be used to advance the clinical development of AGMB-447, a lung-restricted inhaled small molecule inhibitor of ALK5, which is currently in a Phase 1 clinical trial in healthy subjects and patients with idiopathic pulmonary fibrosis (IPF); and the initial clinical development of AGMB-101..."

Financing • P2a data • Crohn's disease • Idiopathic Pulmonary Fibrosis • Liver Cirrhosis

Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline (Businesswire) - "The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5 (TGFβ1R), in patients with fibrostenosing Crohn’s disease (FSCD). Interim data from the Phase 2a STENOVA trial are expected in the first quarter of 2025. In addition, proceeds will be used to advance the clinical development for AGMB-447…as well as initial clinical development of AGMB-101…"

Financing • P2a data • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease